Cerdulatinib is a small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies.[1] It has lowest nM IC50 values against TYK2, JAK1, JAK2, JAK3, FMS, and SYK.[2]
It is being developed by Portola Pharmaceuticals; in September 2018 the FDA granted orphan drug status to cerdulatinib for the treatment of peripheral T-cell lymphoma (PTCL).[3]
See also
References
- ^ Liu D, Mamorska-Dyga A (July 2017). “Syk inhibitors in clinical development for hematological malignancies”. Journal of Hematology & Oncology. 10 (1) 145. doi:10.1186/s13045-017-0512-1. PMC 5534090. PMID 28754125.
- ^ Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, et al. (December 2014). “The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer”. The Journal of Pharmacology and Experimental Therapeutics. 351 (3): 538–48. doi:10.1124/jpet.114.218164. PMID 25253883.
- ^ “Investors – News Release – Portola Pharmaceuticals, Inc”. phx.corporate-ir.net. September 25, 2018.